Sibutsetelo se-Natazia Birth Control

I-Natazia ingumuthi wezipilisi zokulawula ukuzalwa . Le pilisi (eselivele ilayisensi eYurophu ngaphansi kwegama elithi Qlaira) yisisindo sokuqala sokubeletha ngomlomo esithengiswa eMelika. I-Natazia iyingqayizivele ngomqondo wokuthi yiyokuqala nokukhulelwa komlomo kuphela okuqukethe i-estrogen ebizwa nge-estradiol valerate kanye ne-progestin ebizwa nge-dienogest.

Ngaphandle kukaNatazia, wonke amaphilisi okulawula ukuzalwa ahlanganisiwe aqukethe i- ethinyl estradiol . I-Estradiol valerate, i-estrogen yokwenziwa etholakala eNatazia, iguqulwa ibe yi-estradiol emzimbeni wesifazane.

I-Natazia ihluke kumaphilisi omdabu wendabuko ayenziwe ngesilinganiso esisodwa se-estrogen ne- progestin . I-Natazia inikeza ama-hormone ehlukene ngezikhathi ezine kulowo nalowo mjikelezo wezinsuku ezingu-28 wezokwelapha. Amaphilisi anezilinganiso ezihlukahlukene ze-estradiol valerate, kanye ne-estradiol valerate ehlangene ne-dienogest, ngezinsuku ezithile zomjikelezo wosuku lwama-28. I-validate ye-estradiol yehla kusuka ku-3 mg kuya ku- 1 mg ngaphezu kwezinsuku ezingu-28. Iphakheji ngalinye le-Natazia liqukethe amaphilisi alandelayo okumelwe athathwe kulokhu okulandelwayo:

I-Estradiol valerate ayinamandla kakhulu njenge-ethinyl estradiol. Ngenxa yalokhu, i-Natazia ingase ibe inhlanganisela enhle yokukhulelwa kwabesifazane abakhathazekile nge-estrogen ngoba leli pilisi lingase lingabangeli imiphumela emibi ehlobene ne-estrogen .

Imiphumela ye-Natazia Imiphumela:

Njenganoma yiluphi uhlobo lwezokwelapha zokubeletha kwe-hormonal , ungase uthole ezinye imiphumela emibi (ngokuvamile evame emva kwezinyanga ezintathu zokuqala) uma usebenzisa i-Natazia. Imiphumela emibi kakhulu ebikiwe yile pilisi ezine-phasiki yilezi:

Izinzuzo ezingenakuqhathaniswa zeNatazia:

I-Natazia ibiye i-FDA-evunyelwe ukusiza ukunciphisa ukuphuma kwegazi kwabesifazane abanenkathi enzima yenyanga (eyaziwa ngokuthi i- menorrhagia ). Ukwazisa kukaNatazia nolwazi lokuthi "ngokusekelwe ezincwadini zokugcina iziguli, i-amenorrhea (engenayo isikhathi) ivela cishe emaphesenti angu-16 kumjikelezo kubesifazane abasebenzisa iNatazia."

Ukucwaninga kusekela ukuphumelela kukaNatazia ngokusiza abesifazane abanobunzima obukhathini. Ngokucwaninga okungahleliwe, abacwaningi bahlola amaphethini kanye nokulawula umjikelezo emadodeni angama-804 (abaneminyaka eyi-18-50). Laba besifazane banikwe i-Natazia noma iphilisi elilodwa le-hormone, i-ethinyl estradiol ne-levonorgestrel (njenge- Seasonique ne- Amethyst ). Abesifazane besigaba seNatazia babika izinsuku ezincane kakhulu zokuphuza kanye / noma ukuqhathanisa uma kuqhathaniswa nabesifazane emkhakheni wephilisi we-monophasic - ophakathi kwezinsuku ezingu-16 no-21. Abacwaningi baphinde bathola ukuthi ngesikhathi sokuphuma kwabo (okungukuthi, "isikhathi"), abesifazane abasebenzisa uNatazia bachaza ukuphuma kwegazi njengento encane kakhulu futhi bahlambalaza izinsuku ezimbalwa uma kuqhathaniswa neqembu le-monophasic.

Okokugcina, abesifazane abasebenzisa iNatazia nabo bebengenakwenzeka ukuba bangabi negazi.

Ukungabi ne-Ortho Tri-Cyclen Lo Pill:

Ngenxa yokuthi amazinga e-hormone ahlukile kuzo zonke izigaba ezine zamaphilisi, kuzodingeka ulandele izinkomba ezahlukene ngokuya lapho ukhona emphakathini wakho uma ukhohlwa ukuthatha iphilisi (ama). Lokhu okulandelayo kungumthetho omuhle wesithupha okumele ulandelwe (kodwa kufanele uhlole njalo iphilisi ebeka ulwazi oluza nepakethe ngalinye lenyanga). Uma ungakapheli isikhathi esingamahora angu-12 uthatha iphilisi yakho, thatha iphilisi yakho ngokushesha uma ukhumbule bese uthatha iphilisi yakho elandelayo ngesikhathi sakho esivamile (akudingeki usebenzise ukukhulelwa kokubeletha).

Uma usebenzisa i-Natazia, uma usuphelile isikhathi samahora angu-12 futhi ukhohlwa ukuyithatha:

Ukuphumelela kwe-Natazia:

Amaphilisi okulawula ukuzalwa ayingxenye ephumelelayo kakhulu futhi elula yokuvimbela ukukhulelwa . Iphilisi ingu-92-99.7% esebenzayo. Ngokusetshenziswa okujwayelekile, abesifazane abangu-8 kwabangu-100 bazokhulelwa phakathi nonyaka wokuqala wokusebenzisa iphilisi. Ngokusetshenziswa okuphelele, ngaphansi kuka-1 kuzokhulelwa. Kungakhathaliseki uhlobo / inani lama-hormone epilisi, wonke amaphilisi okuhlanganiswa asebenza ngendlela efanayo yokuvimbela ukukhulelwa.

Ungase ukhulelwe kakade noma ungakhulelwa uma ulala ocansini ezinsukwini emva kwamaphilisi alahlekile. Amaphilisi amaningi owawaphuthelwa kanye / noma osondelene nawe ekupheleni komjikelezo, ukwandisa ingozi yokukhulelwa.

I-Natazia ingase ingasebenzi kangcono kwabesifazane abakhuluphele (okungasebenza ku-30% kubo bonke abaseMelika). Ukusebenza kukaNatazia kwabesifazane abane-index mass body (BMI) ye> 30 kg / m2 akukahlolwa.

Izindleko ze-Natazia:

Kubonakala sengathi intengo kaNatazia ibiza kakhulu kunezinye izitho zomzimba ezitholakalayo zomlomo. Njengoba i-Natazia ibhekwa njengomuthi owuhlaza noma imithi yesithathu ngaphansi kwezinhlelo eziningi zomshuwalense wezempilo, ngeke ihlanganiswe noma ingadinga i-copay ephakeme.

Lokhu kuthiwa, ayikho enye indlela ejwayelekile yeNatazia. I-Bayer (ingumkhiqizi) unamalungelo akhethekile ekukhiqizeni nasekudayiseni kwe-Natazia kuze kube ngu-2016 - uma i-patent iphelelwa yisikhathi. Emva kwalesi sikhathi, ezinye izinkampani zezidakamizwa zingakwazi ukuthengisa nokuthengisa i-Natazia ejwayelekile. Ngenxa yokuthi ayikho indlela yama-generic ye-Natazia, ingase ihlanganiswe ngaphandle kwezindleko ezingaphandle kwe-pocket yazo zonke izinhlelo zomshuwalense ezingabonakali.

Ungagcina futhi imali ku-Natazia nge-Bayer Savings Card. Ngemuva kokuqalisa leli khadi (elingabizi lutho), udinga ukuliphrinta bese ulibonisa kumakhemikhali wakho:

Imithombo:

Ahrendt HJ, Makalova D, Parke S, Mellinger U, Mansour D. "Iphethini lokuphuza nokulawula umjikelezo nge-contraradial-oral contraceptive-based: Umjikelezo wesikhombisa, ukuhlolwa okungahleliwe kokuqhathaniswa kwe-estradiol valerate / dienogest kanye ne-ethinyl estradiol / levonorgestrel." Ukwelashwa . 2009; 80: 436-444. Isihloko esigcwele sifinyelelwe ngokubhaliselwe kwangasese.

"I-NATAZIA-estradiol valerate ne-estradiol valerate / kit ye-dienogest." [Bayer HealthCare Pharmaceuticals Inc.]. I-Med Med Daily. Kufinyelelwe: ngomhla ka-4 Disemba 2014.